Berenberg Bank downgraded shares of Victrex (LON:VCT) to a hold rating in a research note published on Tuesday. They currently have GBX 2,600 ($33.97) price target on the stock, down from their previous price target of GBX 2,900 ($37.89).

A number of other equities analysts have also recently issued reports on VCT. UBS Group restated a buy rating and set a GBX 3,600 ($47.04) price objective (up previously from GBX 3,300 ($43.12)) on shares of Victrex in a report on Thursday, October 4th. Morgan Stanley lowered Victrex to an underweight rating and decreased their target price for the company from GBX 2,500 ($32.67) to GBX 2,300 ($30.05) in a research report on Friday, October 12th. Liberum Capital reaffirmed a buy rating on shares of Victrex in a research report on Tuesday, October 16th. Peel Hunt reaffirmed an add rating on shares of Victrex in a research report on Tuesday, December 4th. Finally, Barclays reaffirmed an underweight rating and set a GBX 2,420 ($31.62) target price on shares of Victrex in a research report on Wednesday, December 5th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the stock. Victrex presently has a consensus rating of Hold and an average price target of GBX 2,626.82 ($34.32).

VCT opened at GBX 2,248 ($29.37) on Tuesday. Victrex has a 52-week low of GBX 1,826 ($23.86) and a 52-week high of GBX 2,772 ($36.22).

The company also recently announced a dividend, which will be paid on Friday, February 22nd. Shareholders of record on Thursday, January 31st will be given a dividend of GBX 128.82 ($1.68) per share. The ex-dividend date of this dividend is Thursday, January 31st. This is a positive change from Victrex’s previous dividend of $13.42. This represents a yield of 5.46%.

In other news, insider Richard Armitage bought 1,010 shares of the firm’s stock in a transaction on Wednesday, December 5th. The stock was acquired at an average cost of GBX 2,318 ($30.29) per share, with a total value of £23,411.80 ($30,591.66). Over the last ninety days, insiders have acquired 1,019 shares of company stock valued at $2,367,396.

Victrex Company Profile

Victrex plc, through its subsidiaries, manufactures and sells polymers worldwide. It operates through two segments, Victrex Polymer Solutions and Invibio Biomaterial Solutions. The company offers VICTREX PEEK polymer materials; and biomaterial solutions for use in spine, dental, trauma, knee, cardiovascular, and orthopedic applications.

Featured Article: How Important is Technical Analysis of Stocks

Analyst Recommendations for Victrex (LON:VCT)

Receive News & Ratings for Victrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Victrex and related companies with's FREE daily email newsletter.